검색결과 : 4건
| No. | Article |
|---|---|
| 1 |
cDC1 prime and are licensed by CD4(+)T cells to induce anti-tumour immunity Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT, Bagadia P, Liu TT, Briseno CG, Li LJ, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM Nature, 584(7822), 624, 2020 |
| 2 |
cDC1 prime and are licensed by CD4(+)T cells to induce anti-tumour immunity Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT, Bagadia P, Liu TT, Briseno CG, Li LJ, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM Nature, 584(7822), 624, 2020 |
| 3 |
WDFY4 is required for cross-presentation in response to viral and tumor antigens Theisen DJ, Davidson JT, Briseno CG, Gargaro M, Lauron EJ, Wang QL, Desai P, Durai V, Bagadia P, Brickner JR, Beatty WL, Virgin HW, Gillanders WE, Mosammaparast N, Diamond MS, Sibley LD, Yokoyama W, Schreiber RD, Murphy TL, Murphy KM Science, 362(6415), 694, 2018 |
| 4 |
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Gubin MM, Zhang XL, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SSK, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJM, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD Nature, 515(7528), 577, 2014 |